Keywords: Pizer, Crizotinib, Myeloid leukemia, Bosutinib, NSCLC, Lung cancer, Europe, EMA

Two Pfizer cancer drug candidates, crizotinib and bosutinib, accepted for filing in Europe

Article | 18 August 2011

Print This

The European Medicines Agency has accepted global drugs behemoth Pfizer’s (NYSE: PFE) regulatory submissions for review of two ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in